IN BRIEF: Creo Medical Speedboat Inject cleared for use in Europe

Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical ...

Alliance News 19 June, 2023 | 9:48AM
Email Form Facebook Twitter LinkedIn RSS

Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical endoscopy - Says its Speedboat Inject endoscopy product has been cleared for use in the entire gastrointestinal tract within European markets. Speedboat Inject is already cleared for full use in the gastrointestinal tract for the cutting and coagulation of soft tissue using radio frequency and microwave energy in the US and Asia Pacific regions. It is used for the prevention and treatment of bowel cancer. Adds it already has a "healthy pipeline" of clinicians ready to use the Speedboat Inject device for upper gastrointestinal procedures across Europe, with demonstrations, training and procedures already planned.

Chief Executive Officer Craig Gulliford says: "This clearance opens up possibilities not only to increase the caseloads of existing users, but primarily to introduce Speedboat to a large base of new users."

Current stock price: 35.70 pence, up 12% on Monday

12-month change: down 61%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Creo Medical Group PLC 36.50 GBX 3.40 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures